Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity

 
• By Joseph Haas

As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.

Old buildings on the Grand Place square at the evening, Lille, France - Image
Based in Lille, France, Genfit is one of five companies to reach Phase III in NASH

More from Strategy

More from Business